SG Americas Securities LLC Raises Stock Position in Immunome, Inc. $IMNM

SG Americas Securities LLC raised its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 1,749.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 162,168 shares of the company’s stock after buying an additional 153,399 shares during the period. SG Americas Securities LLC owned about 0.18% of Immunome worth $3,483,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of IMNM. Assetmark Inc. purchased a new position in shares of Immunome in the 3rd quarter worth $39,000. BNP Paribas Financial Markets increased its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares during the period. BIT Capital GmbH bought a new position in Immunome in the third quarter valued at about $69,000. Finally, Russell Investments Group Ltd. purchased a new position in Immunome in the third quarter worth about $76,000. 44.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Stephens cut their price target on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Leerink Partners set a $40.00 price objective on shares of Immunome in a research note on Monday, December 15th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Evercore upped their target price on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Finally, Lake Street Capital increased their price target on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Insider Buying and Selling

In other Immunome news, Director Philip Wagenheim sold 28,200 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total transaction of $582,330.00. Following the sale, the director owned 341,147 shares in the company, valued at approximately $7,044,685.55. This trade represents a 7.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.69% of the company’s stock.

Immunome Stock Down 2.7%

Shares of IMNM opened at $21.84 on Friday. The business has a 50-day simple moving average of $22.42 and a two-hundred day simple moving average of $19.13. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -9.02 and a beta of 2.13. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $27.65.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). On average, equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.